Mathematical modeling of tumorigenesis: Mission possible

Current Opinion in Oncology

Volumn 17, Issue 1, 2005, Pages 39-43

  Komarova, Natalia L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Genetic instability; Multistage carcinogenesis; Mutations; Vascular and avascular tumor growth

Indexed keywords

CANCER GROWTH; CANCER MODEL; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CHROMOSOME ABERRATION; GENE MUTATION; GENETIC STABILITY; HUMAN; MATHEMATICAL MODEL; ONSET AGE; PRIORITY JOURNAL; REVIEW; STATISTICAL MODEL; TUMOR GROWTH; VASCULARIZATION;

AGING; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EVOLUTION, MOLECULAR; HUMANS; INCIDENCE; MODELS, THEORETICAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 13144256695     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000143681.37692.32     Document Type: Review

References (56)

1. Moolgavkar SH, Knudson AG Jr: Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst 1981, 66:1037-1052.
2. Haylock RG, Muirhead CR: Fitting the two-stage model of carcinogenesis to nested case-control data on the Colorado Plateau uranium miners: dependence on data assumptions. Radiat Environ Biophys 2004, 42:257-263.
3. Krewski D, Zielinski JM, Hazelton WD, et al.: The use of biologically based cancer risk models in radiation epidemiology. Radiat Prot Dosimetry 2003, 104:367-376.
4. Frank SA: Somatic mosaicism and cancer: inference based on a conditional Luria-Delbruck distribution. J Theor Biol 2003, 223:405-412. An elegant article describing the accumulation of somatic mutations in embryonic development, with application to two-hit cancers.
5. Floche M, Schwartz L: Cancer death statistics: analogy between epidemiology and critical systems in physics. Med Hypotheses 2004, 62:704-709. An analysis of French cancer death statistics, yielding a large difference between cancers of early and late ages.
6. Frank SA: Genetic variation in cancer predisposition: mutational decay of a robust genetic control network. Proc Natl Acad Sci U S A 2004, 101:8061-8065. An interesting analysis of cancer viewed as a control system. Predisposition mutations in the population are correlated with the number of stages in multistage carcinogenesis.
7. Moolgavkar SH, Luebeck EG: Multistage carcinogenesis and the incidence of human cancer. Genes Chromosomes Cancer 2003, 38:302-306. The paper uses the Moolgavkar-Venzon-Knudson multistage carcinogenesis model in the context of the discussion of the role of genetic instability in cancer progression.
8. Frigyesi A, Gisselsson D, Mitelman F, et al.: Power law distribution of chromosome aberrations in cancer. Cancer Res 2003, 63:7094-7097. The pattern of chromosome aberrations in various cancers is analyzed, and a model is proposed that explains the observed power law distribution.
9. Frigyesi A, Gisselsson D, Hansen GB, et al.: A model for karyotypic evolution in testicular germ cell tumors. Genes Chromosomes Cancer 2004, 40:172-178. A technique is developed, based on statistical analysis of aberrations in cancer, which allows tracing the sequence of chromosome changes in a particular cancer.
10. Preziosi L (ed): Cancer Modeling and Simulation. Chapman & Hall; 2003.
11. Franks SJ, Byrne HM, Mudhar HS, et al.: Mathematical modelling of comedo ductal carcinoma in situ of the breast. Math Med Biol 2003, 20:277-308.
12. Franks SJ, Byrne HM, King JR, et al.: Modelling the early growth of ductal carcinoma in situ of the breast. J Math Biol 2003, 47:424-452. The article presents a mechanistic model of an avascular cylindrical tumor in a duct.
13. Franks SJ, King JR: Interactions between a uniformly proliferating tumour and its surroundings: uniform material properties. Math Med Biol 2003, 20:47-89.
14. Byrne H, Preziosi L: Modelling solid tumour growth using the theory of mixtures. Math Med Biol 2003, 20:341-366.
15. Owen MR, Byrne HM, Lewis CE: Mathematical modelling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites. J Theor Biol 2004, 226:377-391. This article presents a mechanistic model of an avascular growing tumor and studies how drugs can reduce tumor size.
16. Matzavinos A, Chaplain MA, Kuznetsov VA: Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour. Math Med Biol 2004, 21:1-34. A model is presented that describes the interactions of an avascular tumor with the immune system.
17. Friedman A, Tao Y: Analysis of a model of a virus that replicates selectively in tumor cells. J Math Biol 2003, 47:391-423.
18. Mansury Y, Deisboeck TS: The impact of "search precision" in an agent-based tumor model. J Theor Biol 2003, 224:325-337. This article presents a model of tumor cells, which can migrate depending on the nutrition level and toxicity, using a local search algorithm.
19. Guiot C, Degiorgis PG, Delsanto PP, et al.: Does tumor growth follow a "universal law"? J Theor Biol 2003, 225:147-151. This article talks about similarities between prevascular tumor growth and ontogenic growth of organisms, claiming that they obey the same law.
20. Chaplain M, Anderson A: Mathematical modelling of tumour-induced angiogenesis: network growth and structure. Cancer Treat Res 2004, 117:51-75. An excellent review of mathematical modeling of angiogenesis, also describing new advances in the authors' modeling of tumor neovasculature formation.
21. Breward CJ, Byrne HM, Lewis CE: A multiphase model describing vascular tumour growth. Bull Math Biol 2003, 65:609-640. A mechanistic model of vascular tumor growth describing cell migration in response to stress and lack of nutrition.
22. Plank MJ, Sleeman BD: A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies. Math Med Biol 2003, 20:135-181. An individual cell-based mathematical model of angiogenesis is developed and analyzed in the context of the antiangiogenic potential of angiostatin.
23. Alarcon T, Byrne HM, Maini PK: A cellular automaton model for tumour growth in inhomogeneous environment. J Theor Biol 2003, 225:257-274. This article combines an engineering approach to modeling the blood flow through the vasculature with a cellular automaton model of tumor growth.
24. Alarcon T, Byrne HM, Maini PK: Towards whole-organ modelling of tumour growth. Prog Biophys Mol Biol 2004, 85:451-472. A nice article that describes the modeling of tumor growth in which both vascular adaptation and cell-cycle dynamics are taken into account.
25. Araujo RP, McElwain DL: New insights into vascular collapse and growth dynamics in solid tumors. J Theor Biol 2004, 228:335-346. A good example of how a mathematical model of tumorigenesis can be used to address interesting biological questions.
26. Bru A, Albertos S, Luis Subiza J, et al.: The universal dynamics of tumor growth. Biophys J 2003, 85:2948-2961. An excellent article on tumor growth that combines a mathematical model with experiments.
27. Anderson AR, Chaplain MA: Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull Math Biol 1998, 60:857-899.
28. Tee D, DiStefano J 3rd: Simulation of tumor-induced angiogenesis and its response to anti-angiogenic drug treatment: mode of drug delivery and clearance rate dependencies. J Cancer Res Clin Oncol 2004, 130:15-24. This article uses the Anderson-Chaplain model of angiogenic growth to study different regimens and dosages of antiangiogenic treatment.
29. Swanson KR, Bridge C, Murray JD, et al.: Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion. J Neurol Sci 2003, 216:1-10.
30. Swanson KR, Alvord EC Jr, Murray JD: Quantifying efficacy of chemotherapy of brain tumors with homogeneous and heterogeneous drug delivery. Acta Biotheor 2002, 50:223-237.
31. Evans ND, Errington RJ, Shelley M, et al.: A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan. Math Biosci 2004, 189:185-217. This model describes how the effect of topotecan treatment depends on the dosage and method of administration, and puts emphasis on the structural identifiability analysis.
32. Moore H, Li NK: A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. J Theor Biol 2004, 227:513-523. This model studies the interaction among naive and effector T cells and CML cancer cells, and provides a careful analysis of the parameter dependence of the results.
33. Wodarz D: Computational approaches to study oncolytic virus therapy: insights and challenges. Gene Ther Mol Biol 2004, 8:137-146. This article describes a model that helps find optimal characteristics of viruses to result in cancer remission.
34. Moxnes JF, Hausken K: Predicting the concentration level of an anti-cancer drug during treatment of a living organism. Med Hypotheses 2003, 60:498-500. This article presents an empirical model for determining drug concentration depending on intake parameters.
35. Moxnes JF, Haux J, Hausken K: The dynamics of cell proliferation. Med Hypotheses 2004, 62:556-563. This article presents an age-structured model of a cell population and compares it with experimental results for digitoxin-treated cells.
36. Simeoni M, Magni P, Cammia C, et al.: Predictive pharmacokinetic- pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004, 64:1094-1101. An empirical model predicting the drug concentration depending on intake parameters.
37. Basse B, Baguley BC, Marshall ES, et al.: A mathematical model for analysis of the cell cycle in cell lines derived from human tumors. J Math Biol 2003, 47:295-312. This article models a population of cells going through the cell cycle; the results are compared with flow-cytometry measurements of the amount of the DNA in each phase.
38. Basse B, Baguley BC, Marshall ES, et al.: Modelling cell population growth with applications to cancer therapy in human tumour cell lines. Prog Biophys Mol Biol 2004, 85:353-368.
39. Lupi M, Matera G, Branduardi D, et al.: Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach. Cancer Res 2004, 64:2825-2832. This article uses modeling to predict the outcome of various treatment schedules in the context of ovarian cancer cell lines.
40. Montalenti F, Sena G, Capella P, et al.: Simulating cancer cell kinetics after drug treatment: application to cisplatin on ovarian carcinoma. Phys Rev E Stat Nonlin Soft Matter Phys 1999, 57:5877-5887.
41. Stoll BR, Migliorini C, Kadambi A, et al.: A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 2003, 102:2555-2561. This article presents the first model aimed at determining the role of circulating endothelial progenitor cells in tumor neovascularization.
42. Gatenby RA, Gawlinski ET: The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 2003, 63:3847-3854. This article presents a mathematical model based on the acid-mediated tumor invasion hypothesis.
43. Gatenby RA, Vincent TL: An evolutionary model of carcinogenesis. Cancer Res 2003, 63:6212-6220. This article talks about cancer heterogeneity and evolvability of cancers using the elegant theory of fitness generating function.
44. Gatenby RA, Vincent TL: Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. Mol Cancer Ther 2003, 2:919-927.
45. Sole RV, Deisboeck TS: An error catastrophe in cancer? J Theor Biol 2004, 228:47-54. This article uses quasispecies theory to explain the competition between stable and unstable phenotypes in cancer.
46. Komarova NL, Sengupta A, Nowak MA: Mutation-selection networks of cancer initiation: tumor suppressor genes and chromosomal instability. J Theor Biol 2003, 223:433-450. This article considers the inactivation of a tumor suppressor gene with and without chromosomal instability and calculates the rates of cancer initiation for different cases.
47. Komarova NL, Wodarz D: The optimal rate of chromosome loss for the inactivation of tumor suppressor genes in cancer. Proc Natl Acad Sci U S A 2004, 101:7017-7021. This article considers the role of chromosome loss in the context of tumor suppressor gene inactivation and calculates the optimal (for cancer) rate of chromosome loss.
48. Komarova N: Does cancer solve an optimization problem? Cell Cycle 2004, 3. This article explains that chromosomal instability does not occur in cancer simply because it leads to higher mutability, but requires other reasons, like environment or mutagens.
49. Komarova NL, Wodarz D: Evolutionary dynamics of mutator phenotypes in cancer: implications for chemotherapy. Cancer Res 2003, 63:6635-6642. This article examines the role of environmental stress for the selection of genomic instability. Costs and benefits of genomic instability are discussed.
50. Frank SA, Nowak MA: Problems of somatic mutation and cancer. Bioessays 2004, 26:291-299. A comprehensive review of the research of the Frank and Nowak group on cancer as a process of somatic evolution.
51. Michor F, Nowak MA, Frank SA, et al.: Stochastic elimination of cancer cells. Proc R Soc Lond B Biol Sci 2003, 270:2017-2024. This article presents a stochastic model of accumulation of mutations and talks about design principles capable of reducing the risk of cancer.
52. Michor F, Frank SA, May RM, et al.: Somatic selection for and against cancer. J Theor Biol 2003, 225:377-382. This article discusses how tissue compartment size may influence the rate at which mutations are accumulated.
53. Michor F, Iwasa Y, Rajagopalan H, et al.: Linear model of colon cancer initiation. Cell Cycle 2004, 3:358-362.
54. Nowak MA, Michor F, Iwasa Y: The linear process of somatic evolution. Proc Natl Acad Sci U S A 2003, 100:14966-14969. This article presents a stochastic model of tissue renewal and discusses implications for cancer.
55. Calabrese P, Tavare S, Shibata D: Pretumor progression: clonal evolution of human stem cell populations. Am J Pathol 2004, 164:1337-1346. This article presents a model of neutral evolution inside colon stem niches and relates this to the multistage carcinogenesis hypothesis.
56. Kim KM, Calabrese P, Tavare S, et al.: Enhanced stem cell survival in familial adenomatous polyposis. Am J Pathol 2004, 164:1369-1377. This article uses the stem niche dynamical model to explain the experimentally observed methylation pattern diversity in people with and without FAP.